164 results on '"Bouvier-Alias, Magali"'
Search Results
2. Performance of a high-throughput, automated enzyme immunoassay for the detection of SARS-CoV-2 antigen, including in viral “variants of concern”: Implications for clinical use
- Author
-
Fourati, Slim, Soulier, Alexandre, Gourgeon, Aurélie, Khouider, Souraya, Langlois, Camille, Galbin, Arnaud, Bouter, Anne Le, Rodriguez, Christophe, Joanny, Marie, Dublineau, Amélie, Challine, Dominique, Bouvier-Alias, Magali, Chevaliez, Stéphane, Audureau, Étienne, and Pawlotsky, Jean-Michel
- Published
- 2022
- Full Text
- View/download PDF
3. Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen.
- Author
-
Raymond, Stéphanie, Nicot, Florence, Pallier, Coralie, Bellecave, Pantxika, Maillard, Anne, Trabaud, Mary, Morand-Joubert, Laurence, Rodallec, Audrey, Amiel, Corinne, Mourez, Thomas, Bocket, Laurence, Beby-Defaux, Agnès, Bouvier-Alias, Magali, Lambert-Niclot, Sidonie, Charpentier, Charlotte, Malve, Brice, Mirand, Audrey, Dina, Julia, Le Guillou-Guillemette, Hélène, Marque-Juillet, Stéphanie, Signori-Schmuck, Anne, Barin, Francis, Si-Mohamed, Ali, Avettand Fenoel, Véronique, Roussel, Catherine, Calvez, Vincent, Saune, Karine, Marcelin, Anne, Rodriguez, Christophe, Descamps, Diane, and Izopet, Jacques
- Subjects
Adult ,Drug Resistance ,Viral ,Female ,Genetic Variation ,HIV Infections ,HIV-1 ,Humans ,Male ,Mutation ,Rilpivirine ,Viral Load - Abstract
BACKGROUND: Minority resistant variants of human immunodeficiency virus type 1 (HIV-1) could influence the virological response to treatment based on nonnucleoside reverse transcriptase inhibitors (NNRTIs). Data on minority rilpivirine-resistant variants are scarce. This study used next-generation sequencing (NGS) to identify patients harboring minority resistant variants to nucleos(t)ide reverse transcriptase inhibitors and NNRTIs and to assess their influence on the virological response (VR). METHODS: All the subjects, 541 HIV-1-infected patients started a first-line regimen containing rilpivirine. VR was defined as a HIV-1 RNA load 20% in 29% of samples. We identified 43 (8.8%) and 36 (7.4%) patients who harbored rilpivirine-resistant variants with a 1% sensitivity threshold according to the French National Agency for Research on AIDS and Viral Hepatitis and Stanford algorithms, respectively. The VR was 96.9% at month 12. Detection of minority rilpivirine resistant variants was not associated with virological failure (VF). Multivariate analysis indicated that VF at month 12 was associated with a CD4 count
- Published
- 2018
4. Multicenter clinical comparative evaluation of Alinity m HIV-1 assay performance
- Author
-
Braun, Patrick, Glass, Allison, Maree, Leana, Krügel, Maria, Pacenti, Monia, Onelia, Francesco, Gunson, Rory, Goldstein, Emily, Martínez-García, Laura, Galán, Juan-Carlos, Vilas, Alba, D’costa, Jodie, Sameer, Rizmina, Ehret, Robert, Knechten, Heribert, Naeth, Gudrun, Bouvier-Alias, Magali, Marlowe, Natalia, Palm, Michael J., Joseph, Ajith M., Dhein, Jens, Reinhardt, Birgit, Pfeifer, Karin, Lucic, Danijela, and Obermeier, Martin
- Published
- 2020
- Full Text
- View/download PDF
5. Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen
- Author
-
French National Agency for Research on AIDS and Viral Hepatitis (ANRS) AC11 Resistance Study Group, Raymond, Stéphanie, Nicot, Florence, Pallier, Coralie, Bellecave, Pantxika, Maillard, Anne, Trabaud, Mary Anne, Morand-Joubert, Laurence, Rodallec, Audrey, Amiel, Corinne, Mourez, Thomas, Bocket, Laurence, Beby-Defaux, Agnès, Bouvier-Alias, Magali, Lambert-Niclot, Sidonie, Charpentier, Charlotte, Malve, Brice, Mirand, Audrey, Dina, Julia, Le Guillou-Guillemette, Hélène, Marque-Juillet, Stéphanie, Signori-Schmuck, Anne, Barin, Francis, Si-Mohamed, Ali, Fenoel, Véronique Avettand, Roussel, Catherine, Calvez, Vincent, Saune, Karine, Marcelin, Anne Geneviève, Rodriguez, Christophe, Descamps, Diane, and Izopet, Jacques
- Published
- 2018
6. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial
- Author
-
Bourlière, Marc, Rabiega, Pascaline, Ganne-Carrie, Nathalie, Serfaty, Lawrence, Marcellin, Patrick, Barthe, Yoann, Thabut, Dominique, Guyader, Dominique, Hezode, Christophe, Picon, Magali, Causse, Xavier, Leroy, Vincent, Bronowicki, Jean Pierre, Carrieri, Patrizia, Riachi, Ghassan, Rosa, Isabelle, Attali, Pierre, Molina, Jean Michel, Bacq, Yannick, Tran, Albert, Grangé, Jean Didier, Zoulim, Fabien, Fontaine, Hélène, Alric, Laurent, Bertucci, Inga, Bouvier-Alias, Magali, and Carrat, Fabrice
- Published
- 2017
- Full Text
- View/download PDF
7. Omicron BA.1 breakthrough infection drives long-term remodeling of the memory B cell repertoire in vaccinated individuals
- Author
-
Sokal, Aurélien, primary, Barba-Spaeth, Giovanna, additional, Hunault, Lise, additional, Fernández, Ignacio, additional, Broketa, Matteo, additional, Meola, Annalisa, additional, Fourati, Slim, additional, Azzaoui, Imane, additional, Vandenberghe, Alexis, additional, Lagouge-Roussey, Pauline, additional, Broutin, Manon, additional, Roeser, Anais, additional, Bouvier-Alias, Magali, additional, Crickx, Etienne, additional, Languille, Laetitia, additional, Fournier, Morgane, additional, Michel, Marc, additional, Godeau, Bertrand, additional, Gallien, Sébastien, additional, Melica, Giovanna, additional, Nguyen, Yann, additional, Canoui-Poitrine, Florence, additional, Noizat-Pirenne, France, additional, Megret, Jérôme, additional, Pawlotsky, Jean-Michel, additional, Fillatreau, Simon, additional, Reynaud, Claude-Agnès, additional, Weill, Jean-Claude, additional, Rey, Félix A., additional, Bruhns, Pierre, additional, Mahévas, Matthieu, additional, and Chappert, Pascal, additional
- Published
- 2023
- Full Text
- View/download PDF
8. Omicron BA.1 breakthrough infection drives long-term remodeling of the memory B cell repertoire in vaccinated individuals
- Author
-
Sokal, Aurélien, Barba-Spaeth, Giovanna, Hunault, Lise, Fernández, Ignacio, Broketa, Matteo, Meola, Annalisa, Fourati, Slim, Azzaoui, Imane, Vandenberghe, Alexis, Lagouge-Roussey, Pauline, Broutin, Manon, Roeser, Anais, Bouvier-Alias, Magali, Crickx, Etienne, Languille, Laetitia, Fournier, Morgane, Michel, Marc, Godeau, Bertrand, Gallien, Sébastien, Melica, Giovanna, Nguyen, Yann, Canoui-Poitrine, Florence, Noizat-Pirenne, France, Megret, Jérôme, Pawlotsky, Jean-Michel, Fillatreau, Simon, Reynaud, Claude-Agnès, Weill, Jean-Claude, Rey, Félix, Bruhns, Pierre, Mahévas, Matthieu, Chappert, Pascal, Institut Necker Enfants-Malades (INEM - UM 111 (UMR 8253 / U1151)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CIC - CHU Henri Mondor, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Virologie Structurale - Structural Virology, Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Anticorps en thérapie et pathologie - Antibodies in Therapy and Pathology, Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Physiologie, physiopathologie et thérapeutique (ED 394), Sorbonne Université (SU), Centre d'Immunologie et des Maladies Infectieuses (CIMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), CHU Henri Mondor [Créteil], Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Hôpital Henri Mondor, Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Hôpital Cochin [AP-HP], IMRB - CEPIA/'Clinical Epidemiology And Ageing : Geriatrics, Primary Care and Public Health' [Créteil] (U955 Inserm - UPEC), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Etablissement Français du Sang [Créteil], Structure Fédérative de Recherche Necker (SFR Necker - UMS 3633 / US24), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), and This work was funded by the CAPNET (Comité ad-hoc de pilotage national des essaisthérapeutiques et autres recherches, French government) and by the Fondation PrincesseGrace. Assistance Publique – Hôpitaux de Paris (AP-HP, Département de la Recherche Cli-nique et du Développement) was the promotor and sponsor of MEMO-COV-2. Work in theUnit of Structural Virology was funded by Institut Pasteur, Urgence COVID-19 FundraisingCampaign of Institut Pasteur. PB acknowledges funding from the Institut Pasteur and InsitutNational de la Santé et de la Recherche Médicale (INSERM). AS was supported by a Posted’accueil from INSERM.
- Subjects
[SDV]Life Sciences [q-bio] ,[SDV.IMM]Life Sciences [q-bio]/Immunology - Abstract
SummaryHow infection by a viral variant showing antigenic drift impacts a preformed mature human memory B cell (MBC) repertoire remains an open question. Here, we studied the MBC response up to 6 months after Omicron BA.1 breakthrough infection in individuals previously vaccinated with three doses of mRNA vaccine. Longitudinal analysis, using single-cell multi-omics and functional analysis of monoclonal antibodies from RBD-specific MBCs, revealed that a BA.1 breakthrough infection mostly recruited pre-existing cross-reactive MBCs with limitedde novoresponse against BA.1-restricted epitopes. Reorganization of clonal hierarchy and new rounds of germinal center reaction, however, combined to maintain diversity and induce progressive maturation of the MBC repertoire against common Hu-1 and BA.1, but not BA.5-restricted, SARS-CoV-2 Spike RBD epitopes. Such remodeling was further associated with marked improvement in overall neutralizing breadth and potency. These findings have fundamental implications for the design of future vaccination booster strategies.
- Published
- 2023
9. Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination
- Author
-
Sokal, Aurélien, primary, Bastard, Paul, additional, Chappert, Pascal, additional, Barba-Spaeth, Giovanna, additional, Fourati, Slim, additional, Vanderberghe, Alexis, additional, Lagouge-Roussey, Pauline, additional, Meyts, Isabelle, additional, Gervais, Adrian, additional, Bouvier-Alias, Magali, additional, Azzaoui, Imane, additional, Fernández, Ignacio, additional, de la Selle, Andréa, additional, Zhang, Qian, additional, Bizien, Lucy, additional, Pellier, Isabelle, additional, Linglart, Agnès, additional, Rothenbuhler, Anya, additional, Marcoux, Estelle, additional, Anxionnat, Raphael, additional, Cheikh, Nathalie, additional, Léger, Juliane, additional, Amador-Borrero, Blanca, additional, Fouyssac, Fanny, additional, Menut, Vanessa, additional, Goffard, Jean-Christophe, additional, Storey, Caroline, additional, Demily, Caroline, additional, Mallebranche, Coralie, additional, Troya, Jesus, additional, Pujol, Aurora, additional, Zins, Marie, additional, Tiberghien, Pierre, additional, Gray, Paul E., additional, McNaughton, Peter, additional, Sullivan, Anna, additional, Peake, Jane, additional, Levy, Romain, additional, Languille, Laetitia, additional, Rodiguez-Gallego, Carlos, additional, Boisson, Bertrand, additional, Gallien, Sébastien, additional, Neven, Bénédicte, additional, Michel, Marc, additional, Godeau, Bertrand, additional, Abel, Laurent, additional, Rey, Felix A., additional, Weill, Jean-Claude, additional, Reynaud, Claude-Agnès, additional, Tangye, Stuart G., additional, Casanova, Jean-Laurent, additional, and Mahévas, Matthieu, additional
- Published
- 2022
- Full Text
- View/download PDF
10. Performance of 22 Rapid Lateral Flow Tests for SARS-CoV-2 Antigen Detection and Influence of “Variants of Concern”: Implications for Clinical Use
- Author
-
Gourgeon, Aurélie, primary, Soulier, Alexandre, additional, Audureau, Étienne, additional, Khouider, Souraya, additional, Galbin, Arnaud, additional, Langlois, Camille, additional, Bouvier-Alias, Magali, additional, Rodriguez, Christophe, additional, Chevaliez, Stéphane, additional, Pawlotsky, Jean-Michel, additional, and Fourati, Slim, additional
- Published
- 2022
- Full Text
- View/download PDF
11. Detection of numerous HIV-1/MO recombinants in France
- Author
-
De Oliveira, Fabienne, Cappy, Pierre, Lemée, Véronique, Moisan, Alice, Pronier, Charlotte, Bocket, Laurence, Bouvier-Alias, Magali, Chaix, Marie-Laure, Gault, Elyanne, Morvan, Odile, Poveda, Jean-Dominique, Schneider, Véronique, Wirden, Marc, Alessandri-Gradt, Elodie, Mourez, Thomas, and Plantier, Jean-Christophe
- Published
- 2018
- Full Text
- View/download PDF
12. Analysis of mRNA vaccination-elicited RBD-specific memory B cells reveals strong but incomplete immune escape of the SARS-CoV-2 Omicron variant
- Author
-
Sokal, Aurélien, primary, Broketa, Matteo, additional, Barba-Spaeth, Giovanna, additional, Meola, Annalisa, additional, Fernández, Ignacio, additional, Fourati, Slim, additional, Azzaoui, Imane, additional, de La Selle, Andrea, additional, Vandenberghe, Alexis, additional, Roeser, Anais, additional, Bouvier-Alias, Magali, additional, Crickx, Etienne, additional, Languille, Laetitia, additional, Michel, Marc, additional, Godeau, Bertrand, additional, Gallien, Sébastien, additional, Melica, Giovanna, additional, Nguyen, Yann, additional, Zarrouk, Virginie, additional, Canoui-Poitrine, Florence, additional, Noizat-Pirenne, France, additional, Megret, Jérôme, additional, Pawlotsky, Jean-Michel, additional, Fillatreau, Simon, additional, Simon-Lorière, Etienne, additional, Weill, Jean-Claude, additional, Reynaud, Claude-Agnès, additional, Rey, Félix A., additional, Bruhns, Pierre, additional, Chappert, Pascal, additional, and Mahévas, Matthieu, additional
- Published
- 2022
- Full Text
- View/download PDF
13. Immune escape of SARS-CoV-2 Omicron variant from mRNA vaccination-elicited RBD-specific memory B cells.
- Author
-
Sokal, Aurelien, primary, Broketa, Matteo, additional, Meola, Annalisa, additional, Barba-Spaeth, Giovanna, additional, Fernandez, Ignacio, additional, Fourati, Slim, additional, Azzaoui, Imane, additional, de La Selle, Andrea, additional, Vandenberghe, Alexis, additional, Roeser, Anais, additional, Bouvier-Alias, Magali, additional, Crickx, Etienne, additional, Languille, Laetitia, additional, Michel, Marc, additional, Godeau, Bertrand, additional, Gallien, Sebastien, additional, Melica, Giovanna, additional, Nguyen, Yann, additional, Zarrouk, Virginie, additional, Canoui-Poitrine, Florence, additional, Noizat-Pirenne, France, additional, Megret, Jerome, additional, Pawlotsky, Jean-Michel, additional, Fillatreau, Simon, additional, Simon-Loriere, Etienne, additional, Weill, Jean-Claude, additional, Reynaud, Claude-Agnes, additional, Rey, Felix A., additional, Bruhns, Pierre, additional, Chappert, Pascal, additional, and Mahevas, Matthieu, additional
- Published
- 2021
- Full Text
- View/download PDF
14. mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants
- Author
-
Sokal, Aurélien, primary, Barba-Spaeth, Giovanna, additional, Fernández, Ignacio, additional, Broketa, Matteo, additional, Azzaoui, Imane, additional, de La Selle, Andréa, additional, Vandenberghe, Alexis, additional, Fourati, Slim, additional, Roeser, Anais, additional, Meola, Annalisa, additional, Bouvier-Alias, Magali, additional, Crickx, Etienne, additional, Languille, Laetitia, additional, Michel, Marc, additional, Godeau, Bertrand, additional, Gallien, Sébastien, additional, Melica, Giovanna, additional, Nguyen, Yann, additional, Zarrouk, Virginie, additional, Canoui-Poitrine, Florence, additional, Pirenne, France, additional, Mégret, Jérôme, additional, Pawlotsky, Jean-Michel, additional, Fillatreau, Simon, additional, Bruhns, Pierre, additional, Rey, Felix A., additional, Weill, Jean-Claude, additional, Reynaud, Claude-Agnès, additional, Chappert, Pascal, additional, and Mahévas, Matthieu, additional
- Published
- 2021
- Full Text
- View/download PDF
15. La diversité du répertoire des cellules B mémoires fait face aux variants du SRAS-CoV2 après la vaccination par ARNm chez les individus naïfs et guéris
- Author
-
Chappert, Pascal, primary, Sokal, Aurélien, additional, Barba-Spaeth, Giovanna, additional, Fernandez, Ignacio, additional, Broketta, Matteo, additional, Azzaoui, Imane, additional, De La Selle, Andrea, additional, Vandenberghe, Alexis, additional, Fourati, Slim, additional, Meola, Annalisa, additional, Bouvier-Alias, Magali, additional, Cricks, Etienne, additional, Languille, Laetitia, additional, Michel, Marc, additional, Godeau, Bertrand, additional, Canoui-Poitrine, Florence, additional, Pirenne, France, additional, Megret, Jérôme, additional, Pawlotsky, Jean-Michel, additional, Bruhns, Pierre, additional, Rey, Felix, additional, Weill, Jean-Claude, additional, Reynaud, Claude-Agnès, additional, and Mahévas, Matthieu, additional
- Published
- 2021
- Full Text
- View/download PDF
16. Retreatment With Sofosbuvir and Simeprevir of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed a Daclatasvir-Containing Regimen
- Author
-
Hézode, Christophe, Chevaliez, Stéphane, Scoazec, Giovanna, Soulier, Alexandre, Varaut, Anne, Bouvier-Alias, Magali, Ruiz, Isaac, Roudot-Thoraval, Françoise, Mallat, Ariane, Féray, Cyrille, and Pawlotsky, Jean-Michel
- Published
- 2016
- Full Text
- View/download PDF
17. Memory B cells control SARS-CoV-2 variants upon mRNA vaccination of naive and COVID-19 recovered individuals
- Author
-
Sokal, Aurélien, primary, Barba-Spaeth, Giovanna, additional, Fernández, Ignacio, additional, Broketa, Matteo, additional, Azzaoui, Imane, additional, La Selle, Andrea de, additional, Vandenberghe, Alexis, additional, Fourati, Slim, additional, Roeser, Anais, additional, Meola, Annalisa, additional, Bouvier-Alias, Magali, additional, Crickx, Etienne, additional, Languille, Laetitia, additional, Michel, Marc, additional, Godeau, Bertrand, additional, Gallien, Sébastien, additional, Melica, Giovanna, additional, Nguyen, Yann, additional, Zarrouk, Virginie, additional, Canoui-Poitrine, Florence, additional, Noizat-Pirenne, France, additional, Megret, Jérôme, additional, Pawlotsky, Jean-Michel, additional, Fillatreau, Simon, additional, Bruhns, Pierre, additional, Rey, Felix A., additional, Weill, Jean-Claude, additional, Reynaud, Claude-Agnès, additional, Chappert, Pascal, additional, and Mahévas, Matthieu, additional
- Published
- 2021
- Full Text
- View/download PDF
18. Diagnosis and Monitoring of Hepatitis B Virus Infection Using the Cobas® HBV Test for Use on the Cobas® 4800 System
- Author
-
Ortonne, Valérie, primary, Wlassow, Mélanie, additional, Bouvier-Alias, Magali, additional, Melica, Giovana, additional, Poveda, Jean-Dominique, additional, Laperche, Syria, additional, Pawlotsky, Jean-Michel, additional, and Chevaliez, Stephane, additional
- Published
- 2021
- Full Text
- View/download PDF
19. Maturation and persistence of the anti-SARS-CoV-2 memory B cell response
- Author
-
Sokal, Aurélien, primary, Chappert, Pascal, additional, Barba-Spaeth, Giovanna, additional, Roeser, Anais, additional, Fourati, Slim, additional, Azzaoui, Imane, additional, Vandenberghe, Alexis, additional, Fernandez, Ignacio, additional, Meola, Annalisa, additional, Bouvier-Alias, Magali, additional, Crickx, Etienne, additional, Beldi-Ferchiou, Asma, additional, Hue, Sophie, additional, Languille, Laetitia, additional, Michel, Marc, additional, Baloul, Samia, additional, Noizat-Pirenne, France, additional, Luka, Marine, additional, Mégret, Jérôme, additional, Ménager, Mickaël, additional, Pawlotsky, Jean-Michel, additional, Fillatreau, Simon, additional, Rey, Felix A., additional, Weill, Jean-Claude, additional, Reynaud, Claude-Agnès, additional, and Mahévas, Matthieu, additional
- Published
- 2021
- Full Text
- View/download PDF
20. Surveillance of HIV-1 primary infections in France from 2014 to 2016: toward stable resistance, but higher diversity, clustering and virulence?
- Author
-
Visseaux, Benoit, Assoumou, Lambert, Grude, Maxime, Carles, Marie-Josée, Meyer, Laurence, Roussel, Catherine, Le Guillou-Guillemette, H., Ducancelle, A., Courdavault, L, Alloui, C, Honore, P, Lepiller, Q., Bettinger, D., Bellecave, P., Pinson-Recordon, P, Tumiotto, Camille, Vallet, Sophie, Payan, C., Duthe, J, Leroux, M., Dina, Julia, Vabret, A., Mirand, A., Henquell, C., Bouvier-Alias, Magali, Simohamed, A, dos Santos, G, yerly, S, Gaille, C, Caveng, W, Chapalay, S, Calmy, A., Signori-Schmuck, Anne, Morand, Patrice, Pallier, Coralie, Raho-Moussa, M, Mole, M, Dulucq, M-J, Bocket, Laurence, Alidjinou, K, Ranger-Rogez, S, Trabaud, Mary-Anne, Icard, V, Tardy, J., Tamalet, C., Delamare, C, Montes, Brigitte, Schvoerer, E., Fenaux, H., Rodallec, A., André-Garnier, E., Ferre, Virginie, de Monte, Anne, Guigon, A., Guinard, J., Descamps, Diane, Charpentier, C., Peytavin, G., Tremaux, P, Avettand-Fenoel, V., Soulie, C., Malet, I., Wirden, Marc, Marcelin, A, Calvez, V., Flandre, P., Costagliola, D, Morand-Joubert, Laurence, Lambert-Niclot, S., Fofana, D, Boukli, N., Delaugerre, C., Chaix, Marie-Laure, Mahjoub, Nadia, Amiel, Corinne, Giraudeau, G, Beby-Defaux, A., Plainchamp, D, Maillard, Anne, Alessandri-Gradt, E, Leoz, M, Plantier, Jean-Christophe, Gantner, P, Delagreverie, H, Fafi-Kremer, Samira, Fischer, P, Raymond, Stéphanie, Izopet, Jacques, Chiabrando, J, Stefic, Karl, Barin, F., Fajole, G, Burgault, O, Marque-Juillet, S, Service de Virologie [CHU Bichat], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Epidémiologie, stratégies thérapeutiques et virologie cliniques dans l'infection à VIH, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Immuno-Rhumatologie Moléculaire, Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Microbiologie cellulaire et moléculaire et pathogénicité (MCMP), Université Bordeaux Segalen - Bordeaux 2-Centre National de la Recherche Scientifique (CNRS), Université de Bordeaux (UB), virology, Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Centre de recherche sur l'hétéroepitaxie et ses applications (CRHEA), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), Service de Virologie [CHU Caen], CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), CHU Clermont-Ferrand, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Geneva University Hospital (HUG), Institut de biologie structurale (IBS - UMR 5075 ), Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Laboratoire de virologie [CHU Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institut Hospitalier Universitaire Méditerranée Infection (IHU Marseille), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Laboratoire de Chimie Physique et Microbiologie pour les Matériaux et l'Environnement (LCPME), Institut de Chimie du CNRS (INC)-Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Service de virologie [CHU Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Hôtel-Dieu de Nantes, Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Radiologie [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Pharmacie de l'Hôpital Bichat, Centre de Recherches Pétrographiques et Géochimiques (CRPG), Institut national des sciences de l'Univers (INSU - CNRS)-Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Service de Virologie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), CHU Saint-Antoine [AP-HP], Service de microbiologie [Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Génétique et Ecologie des Virus, Génétique des Virus et Pathogénèse des Maladies Virales, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de Virologie [CHU Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Centre d'Immunologie et des Maladies Infectieuses (CIMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Unité de Rétrovirologie, Hôpital Pontchaillou, Normandie Université (NU), Laboratoire de Virologie, CHU Strasbourg, Laboratoire de Virologie [Toulouse], CHU Toulouse [Toulouse], Service de bactériologie-virologie [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau, Centre national de référence du VIH INSERM U966, Université de Tours (UT), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Besançon, Université de Franche-Comté (UFC), Université Grenoble Alpes (UGA), Université Nice Sophia Antipolis (... - 2019) (UNS), Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Unit for Virus Host-Cell Interactions [Grenoble] (UVHCI), Université Joseph Fourier - Grenoble 1 (UJF)-European Molecular Biology Laboratory [Grenoble] (EMBL)-Centre National de la Recherche Scientifique (CNRS), Institut de biologie structurale (IBS - UMR 5075), Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes (UGA)-Centre National de la Recherche Scientifique (CNRS), Institut Hospitalier Universitaire Méditerranée Infection (IHU AMU), Stress, Immunité, Pathogènes (SIMPA), Université de Lorraine (UL), Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Physiologie, Environnement et Génétique pour l'Animal et les Systèmes d'Elevage [Rennes] (PEGASE), AGROCAMPUS OUEST-Institut National de la Recherche Agronomique (INRA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], CHU Saint-Antoine [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7), Centre d'Immunologie et de Maladies Infectieuses (CIMI), Université de Tours, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10, Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Service de virologie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Hôpital Bretonneau-Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7)
- Subjects
Male ,Etravirine ,HIV Infections ,Men who have sex with men ,Sexual and Gender Minorities ,chemistry.chemical_compound ,Pre-exposure prophylaxis ,0302 clinical medicine ,Pharmacology (medical) ,030212 general & internal medicine ,Phylogeny ,ComputingMilieux_MISCELLANEOUS ,0303 health sciences ,education.field_of_study ,Virulence ,biology ,[SDE.IE]Environmental Sciences/Environmental Engineering ,Middle Aged ,Viral Load ,3. Good health ,Integrase ,Infectious Diseases ,Rilpivirine ,Epidemiological Monitoring ,[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,Female ,France ,Viral load ,medicine.drug ,Adult ,Microbiology (medical) ,Genotype ,Anti-HIV Agents ,[SDE.MCG]Environmental Sciences/Global Changes ,Population ,Evolution, Molecular ,03 medical and health sciences ,Drug Resistance, Viral ,medicine ,Humans ,education ,Pharmacology ,030306 microbiology ,Genetic Variation ,Sequence Analysis, DNA ,[SDE.ES]Environmental Sciences/Environmental and Society ,Virology ,chemistry ,Mutation ,HIV-1 ,biology.protein ,[SDE.BE]Environmental Sciences/Biodiversity and Ecology - Abstract
ObjectivesPatients with primary HIV-1 infection (PHI) are a particular population, giving important insight about ongoing evolution of transmitted drug resistance-associated mutation (TDRAM) prevalence, HIV diversity and clustering patterns. We describe these evolutions of PHI patients diagnosed in France from 2014 to 2016.MethodsA total of 1121 PHI patients were included. TDRAMs were characterized using the 2009 Stanford list and the French ANRS algorithm. Viral subtypes and recent transmission clusters (RTCs) were also determined.ResultsPatients were mainly MSM (70%) living in the Paris area (42%). TDRAMs were identified among 10.8% of patients and rose to 18.6% when including etravirine and rilpivirine TDRAMs. Prevalences of PI-, NRTI-, first-generation NNRTI-, second-generation NNRTI- and integrase inhibitor-associated TDRAMs were 2.9%, 5.0%, 4.0%, 9.4% and 5.4%, respectively. In a multivariable analysis, age >40 years and non-R5 tropic viruses were associated with a >2-fold increased risk of TDRAMs. Regarding HIV diversity, subtype B and CRF02_AG (where CRF stands for circulating recombinant form) were the two main lineages (56% and 20%, respectively). CRF02_AG was associated with higher viral load than subtype B (5.83 versus 5.40 log10 copies/mL, P = 0.004). We identified 138 RTCs ranging from 2 to 14 patients and including overall 41% from the global population. Patients in RTCs were younger, more frequently born in France and more frequently MSM.ConclusionsSince 2007, the proportion of TDRAMs has been stable among French PHI patients. Non-B lineages are increasing and may be associated with more virulent CRF02_AG strains. The presence of large RTCs highlights the need for real-time cluster identification to trigger specific prevention action to achieve better control of the epidemic.
- Published
- 2019
21. Maturation and persistence of the anti-SARS-CoV-2 memory B cell response
- Author
-
Sokal, Aurélien, primary, Chappert, Pascal, additional, Roeser, Anais, additional, Barba-Spaeth, Giovanna, additional, Fourati, Slim, additional, Azzaoui, Imane, additional, Vandenberghe, Alexis, additional, Fernandez, Ignacio, additional, Bouvier-Alias, Magali, additional, Crickx, Etienne, additional, Ferchiou, Asma Beldi, additional, Hue, Sophie, additional, Languille, Laetitia, additional, Baloul, Samia, additional, Noizat-Pirenne, France, additional, Luka, Marine, additional, Megret, Jérôme, additional, Ménager, Mickaël, additional, Pawlotsky, Jean-Michel, additional, Fillatreau, Simon, additional, Rey, Felix A, additional, Weill, Jean-Claude, additional, Reynaud, Claude-Agnès, additional, and Mahévas, Matthieu, additional
- Published
- 2020
- Full Text
- View/download PDF
22. Interferon-ribavirin in association with stavudine has no impact on plasma human immunodeficiency virus (HIV) type 1 level in patients coinfected with HIV and Hepatitis C virus: a CORIST-ANRS HC1 trial. (HIV/AIDS)
- Author
-
Salmon-Ceron, Dominique, Lassalle, Regis, Pruvost, Alain, Benech, Henri, Bouvier-Alias, Magali, Payan, Christopher, Goujard, Cecile, Bonnet, Eric, Zoulim, Fabien, Morlat, Philippe, Sogni, Philippe, Perusat, Sophie, Treluyer, Jean-Marc, and Chene, Genevieve
- Subjects
Ribavirin -- Dosage and administration ,Ribavirin -- Evaluation ,Interferon -- Dosage and administration ,Interferon -- Evaluation ,Stavudine -- Dosage and administration ,Stavudine -- Evaluation ,Hepatitis C -- Drug therapy ,HIV infection -- Drug therapy ,Health ,Health care industry - Published
- 2003
23. The new Cobas AmpliPrep-Cobas TaqMan (CAP/CTM) real-time PCR assay accurately quantifies HCV genotype 4 RNA in blood: 1009
- Author
-
Chevaliez, Stephane, Bouvier-Alias, Magali, Poveda, Jean-Dominique, and Pawlotsky, Jean-Michel
- Published
- 2012
24. Erythrocyte and plasma ribavirin concentrations in the assessment of early and sustained virological responses to pegylated interferon-alpha 2a and ribavirin in patients coinfected with hepatitis C virus and HIV
- Author
-
Dominguez, Stéphanie, Ghosn, Jade, Cassard, Bruno, Melica, Giovanna, Poizot-Martin, Isabelle, Solas, Caroline, Lascaux, Anne-Sophie, Bouvier-Alias, Magali, Katlama, Christine, Lévy, Yves, and Peytavin, Gilles
- Published
- 2012
- Full Text
- View/download PDF
25. Maraviroc-containing regimen suppresses HIV replication in the cerebrospinal fluid of patients with neurological symptoms
- Author
-
Melica, Giovanna, Canestri, Ana, Peytavin, Gilles, Lelievre, Jean D, Bouvier-Alias, Magali, Clavel, Cyril, Calvez, Vincent, Lascaux, Anne S, Katlama, Christine, and Levy, Yves
- Published
- 2010
- Full Text
- View/download PDF
26. The Cobas AmpliPrep-Cobas TaqMan real-time polymerase chain reaction assay fails to detect hepatitis C virus RNA in highly viremic genotype 4 clinical samples#
- Author
-
Chevaliez, Stéphane, Bouvier-Alias, Magali, Castéra, Laurent, and Pawlotsky, Jean-Michel
- Published
- 2009
- Full Text
- View/download PDF
27. Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction–based method
- Author
-
Chevaliez, Stéphane, Bouvier-Alias, Magali, Brillet, Rozenn, and Pawlotsky, Jean-Michel
- Published
- 2007
- Full Text
- View/download PDF
28. A novel standardized deep sequencing-based assay for hepatitis C virus genotype determination
- Author
-
Rodriguez, Christophe, primary, Soulier, Alexandre, additional, Demontant, Vanessa, additional, Poiteau, Lila, additional, Mercier-Darty, Mélanie, additional, Bouvier-Alias, Magali, additional, Pawlotsky, Jean-Michel, additional, and Chevaliez, Stéphane, additional
- Published
- 2018
- Full Text
- View/download PDF
29. 25‐OH vitamin D level has no impact on the efficacy of antiviral therapy in naïve genotype 1 HCV‐infected patients
- Author
-
Belle, Arthur, primary, Gizard, Emmanuel, additional, Conroy, Guillaume, additional, Lopez, Anthony, additional, Bouvier‐Alias, Magali, additional, Rouanet, Stéphanie, additional, Peyrin‐Biroulet, Laurent, additional, Pawlotsky, Jean‐Michel, additional, and Bronowicki, Jean‐Pierre, additional
- Published
- 2017
- Full Text
- View/download PDF
30. HIV and hepatitis C virus RNA in seronegative organ and tissue donors
- Author
-
Challine, Dominique, Pellegrin, Bertrand, Bouvier-Alias, Magali, Rigot, Pierrette, Laperche, Liliane, and Pawlotsky, Jean-Michel
- Subjects
Hepatitis C virus -- Risk factors ,HIV infection -- Risk factors ,Organ donors -- Health aspects ,Organ donors -- Risk factors - Published
- 2004
31. HIV-1/M+O INTERGROUP DUAL INFECTIONS AND ASSOCIATED HIV-MO RECOMBINANTS IN FRANCE FROM 2004 TO 2014
- Author
-
Cappy, Pierre, de Oliveira, Fabienne, Lemée, Veronique, Gaillard, Jean-Louis, Bocquet, Laurence, Poveda, Jean-Dominique, Bouvier-Alias, Magali, Maillard, Anne, Mourez, Thomas, Plantier, Jean-Christophe, Laboratoire de virologie [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Service de Microbiologie et Hygiène [AP-HP Hôpital Ambroise-Paré], Hôpital Ambroise Paré [AP-HP], Laboratoire de virologie [CHU Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Laboratoire CERBA [Saint Ouen l'Aumône], Laboratoire de Virologie CHU Henri Mondor, Laboratoire de Virologie [Rennes] = Virology [Rennes], CHU Pontchaillou [Rennes], and Mzembaba, Sandy
- Subjects
[SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology ,[SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,[SDV.MP] Life Sciences [q-bio]/Microbiology and Parasitology ,ComputingMilieux_MISCELLANEOUS ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology - Abstract
International audience
- Published
- 2015
32. Naturally Occurring Resistance-Associated Variants of Hepatitis C Virus Protease Inhibitors in Poor Responders to Pegylated Interferon-Ribavirin
- Author
-
Larrat, Sylvie, Vallet, Sophie, David-Tchouda, Sandra, Caporossi, Alban, Margier, Jennifer, Ramière, Christophe, Scholtès, Caroline, Haïm-Boukobza, Stéphanie, Roque-Afonso, Anne-Marie, Besse, Bernard, André-Garnier, Elisabeth, Mohamed, Sofiane, Halfon, Philippe, Pivert, Adeline, Leguillou-Guillemette, Hélène, Abravanel, Florence, Guivarch, Matthieu, Mackiewicz, Vincent, Lada, Olivier, Mourez, Thomas, Plantier, Jean-Christophe, Baazia, Yazid, Alain, Sophie, Hantz, Sébastien, Thibault, Vincent, Gaudy-Graffin, Catherine, Bouvet, Dorine, Mirand, Audrey, Henquell, Cécile, Gozlan, Joël, Lagathu, Gisèle, Pronier, Charlotte, Velay, Aurélie, SCHVOERER, Evelyne, Trimoulet, Pascale, Fleury, Hervé, Bouvier-Alias, Magali, BROCHOT, Etienne, Duverlie, Gilles, Maylin, Sarah, Gouriou, Stéphanie, Pawlotsky, Jean-Michel, Morand, Patrice, Plantier, Christophe, Tang, Y.-W., Unit for Virus Host-Cell Interactions [Grenoble] (UVHCI), Université Joseph Fourier - Grenoble 1 (UJF)-European Molecular Biology Laboratory [Grenoble] (EMBL)-Centre National de la Recherche Scientifique (CNRS), Laboratoire Universitaire de Biodiversité et Ecologie Microbienne (LUBEM), Université de Brest (UBO), Centre d'Investigation Clinique - Innovation Technologique - INSERM - CHU de Grenoble (CIC-IT Grenoble (CIT803)), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Grenoble Alpes - UFR Médecine (UGA UFRM), Université Grenoble Alpes (UGA), Centre Hospitalier Universitaire [Grenoble] (CHU), Biologie cellulaire des infections virales – Cell biology of viral infection, Centre International de Recherche en Infectiologie - UMR (CIRI), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Cancérologie de Lyon (CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Laboratoire de virologie, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Paul Brousse, Hôtel-Dieu de Nantes, Alphabio Laboratory, Hôpital Européen [Fondation Ambroise Paré - Marseille], Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Centre de Physiopathologie Toulouse Purpan (ex IFR 30 et IFR 150) (CPTP), Centre National de la Recherche Scientifique (CNRS)-Université Toulouse III - Paul Sabatier (UPS), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Beaujon, Centre de recherche sur l'Inflammation (CRI), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Rouen, Normandie Université (NU), Service de bactériologie-Virologie-Hygiène [Avicenne], Université Paris 13 (UP13)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Avicenne, Université de Limoges (UNILIM), Service de Bactériologie, Virologie, Hygiène [CHU Limoges], CHU Limoges, CHU Pontchaillou [Rennes], Morphogénèse et antigénicité du VIH et du virus des Hépatites (MAVIVH), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM), Epidémiologie et pathogénie des infections à entérovirus (EPIE), Université d'Auvergne - Clermont-Ferrand I (UdA), Laboratoire Microorganismes : Génome et Environnement - Clermont Auvergne (LMGE), Université Clermont Auvergne (UCA)-Centre National de la Recherche Scientifique (CNRS), CHU Saint-Antoine [APHP], Virology Laboratory, General Hospital Papageorgiou, Service de Virologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Stress, Immunité, Pathogènes (SIMPA), Université de Lorraine (UL), Service de virologie et d'immunologie biologique, CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Microbiologie cellulaire et moléculaire et pathogénicité (MCMP), Université Bordeaux Segalen - Bordeaux 2-Centre National de la Recherche Scientifique (CNRS), Centre National de Référence Virus des hépatites B, C et Delta, Institut National de la Transfusion Sanguine [Paris] (INTS)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Unité de Virologie clinique et fondamentale EA 4294, CHU Amiens-Picardie, Institut de biologie de Lille - IBL (IBLI), Université de Lille, Sciences et Technologies-Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Centre National de la Recherche Scientifique (CNRS)-Université de Lille, Droit et Santé, Laboratoire de Virologie, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Laboratoire de virologie moléculaire et structurale, CHU Grenoble, Centre National de la Recherche Scientifique (CNRS)-European Molecular Biology Laboratory [Grenoble] (EMBL)-Université Joseph Fourier - Grenoble 1 (UJF), Laboratoire de Parasitologie et Mycologiede [CHRU Brest], Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Unité d'évaluation clinique et médico-économique [CHU Grenoble] (Département de la recherche clinique et de l'innovation), Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 (TIMC-IMAG), VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF), Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Virologie [HCL-Hôpital de la Croix Rousse], Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Service de Virologie [Villejuif], Hôpital Paul Brousse, Université Paris-Sud - Paris 11 - Faculté de médecine (UP11 UFR Médecine), Université Paris-Sud - Paris 11 (UP11), Laboratoire de Virologie [CHU Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), ALPHABIO - Laboratoire de biologie médicale, Laboratoire de virologie [CHU Angers], PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Laboratoire de Virologie [CHU Purpan, Toulouse], Institut Fédératif de Biologie (IFB) - Hôpital Purpan, Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Laboratoire de virologie [Rouen], Hôpital Charles Nicolle [Rouen]-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Département de microbiologie : Bactério, Virologie, Parasito, Hygiène, Université Paris 13 (UP13)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Avicenne [AP-HP], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de bactériologie-virologie [Tours], Hôpital Bretonneau-Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre national de référence du VIH INSERM U966, Université de Tours (UT), CHU Clermont-Ferrand, Laboratoire de Virologie [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Laboratoire de Virologie [Rennes] = Virology [Rennes], Institut National de la Transfusion Sanguine [Paris] (INTS)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Laboratoire de bactériologie - hygiène [CHU Amiens], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Hopital Saint-Louis [AP-HP] (AP-HP), Unit for Virus Host-Cell Interactions [Grenoble] ( UVHCI ), Université Joseph Fourier - Grenoble 1 ( UJF ) -European Molecular Biology Laboratory [Grenoble] ( EMBL ) -Centre National de la Recherche Scientifique ( CNRS ), Laboratoire Universitaire de Biodiversité et Ecologie Microbienne ( LUBEM ), Université de Brest ( UBO ), ThEMAS, Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble ( TIMC-IMAG ), Université Joseph Fourier - Grenoble 1 ( UJF ) -Institut polytechnique de Grenoble - Grenoble Institute of Technology ( Grenoble INP ) -IMAG-Institut d'Enseignement Supérieur et de Recherche en Alimentation, Santé Animale, Sciences Agronomiques et de l'Environnement ( VetAgro Sup ) -Centre National de la Recherche Scientifique ( CNRS ) -Université Grenoble Alpes ( UGA ) -Université Joseph Fourier - Grenoble 1 ( UJF ) -Institut polytechnique de Grenoble - Grenoble Institute of Technology ( Grenoble INP ) -IMAG-Institut d'Enseignement Supérieur et de Recherche en Alimentation, Santé Animale, Sciences Agronomiques et de l'Environnement ( VetAgro Sup ) -Centre National de la Recherche Scientifique ( CNRS ) -Université Grenoble Alpes ( UGA ) -CHU Grenoble, Université Joseph Fourier - Grenoble 1 ( UJF ) -CHU Grenoble-CHU Grenoble, Pathogénèse et traitement de l'hépatite fulminante et du cancer du foie, Université Paris-Sud - Paris 11 ( UP11 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université Grenoble Alpes - UFR Médecine ( UGA UFRM ), Université Grenoble Alpes ( UGA ), Internal Medicine and Infectious Diseases Department, European Hospital and Alphabio Laboratory, Centre Hospitalier Universitaire d'Angers ( CHU Angers ), PRES Université Nantes Angers Le Mans ( UNAM ), Laboratoire de Virologie [Toulouse], CHU Toulouse [Toulouse], Service d'hépatologie, Assistance publique - Hôpitaux de Paris (AP-HP) ( APHP ) -Université Paris Diderot - Paris 7 ( UPD7 ) -Hôpital Beaujon, Hôpital Bichat - Claude Bernard, Centre de recherche sur l'Inflammation ( CRI ), Université Paris Diderot - Paris 7 ( UPD7 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Institut de Recherche Biomédicale des Armées ( IRBA ), CHU Avicenne, Service de virologie, Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Assistance publique - Hôpitaux de Paris (AP-HP) ( APHP ) -CHU Pitié-Salpêtrière [APHP], Morphogénèse et antigénicité du VIH et du virus des Hépatites ( MAVIVH ), Université de Tours-Centre Hospitalier Régional Universitaire de Tours-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre de Calcul de l'IN2P3 ( CC-IN2P3 ), Institut National de Physique Nucléaire et de Physique des Particules du CNRS ( IN2P3 ) -Centre National de la Recherche Scientifique ( CNRS ), CHU Strasbourg, Virology Laboratory, Bordeaux University Hospital, Bordeaux, France, Microbiologie cellulaire et moléculaire et pathogénicité ( MCMP ), Université Bordeaux Segalen - Bordeaux 2-Centre National de la Recherche Scientifique ( CNRS ), Faculté de Médecine, CHU Henri Mondor, Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Laboratoire Virologie [CHU Toulouse], Institut Fédératif de Biologie (IFB), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle Biologie [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Hôpital Charles Nicolle [Rouen], Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau, SCHVOERER, Evelyne, Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Saint-Antoine [AP-HP], Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Département de microbiologie : Bactério, Virologie, Parasito, Hygiène-Hôpital Charles Nicolle [Rouen]-CHU Rouen, and Université de Tours
- Subjects
Male ,Hepacivirus ,Viral Nonstructural Proteins ,medicine.disease_cause ,Gastroenterology ,Telaprevir ,chemistry.chemical_compound ,Pegylated interferon ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,MESH: Hepacivirus ,MESH: Treatment Outcome ,MESH: Inhibitory Concentration 50 ,[SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,MESH: Aged ,education.field_of_study ,MESH: Drug Resistance, Viral ,MESH: Middle Aged ,MESH: Protease Inhibitors ,Hepatitis C ,Middle Aged ,3. Good health ,MESH: Hepatitis C, Chronic ,Treatment Outcome ,MESH: Oligopeptides ,[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Female ,MESH: Interferon-alpha ,Viral load ,Oligopeptides ,medicine.drug ,Microbiology (medical) ,MESH: Antiviral Agents ,Adult ,medicine.medical_specialty ,Proline ,Hepatitis C virus ,Population ,Mutation, Missense ,Antiviral Agents ,Inhibitory Concentration 50 ,MESH: Ribavirin ,Internal medicine ,Boceprevir ,Virology ,Drug Resistance, Viral ,Ribavirin ,medicine ,Humans ,Protease Inhibitors ,education ,Aged ,Retrospective Studies ,MESH: Mutation, Missense ,MESH: Humans ,MESH: Proline ,business.industry ,Interferon-alpha ,MESH: Adult ,MESH: Retrospective Studies ,Hepatitis C, Chronic ,medicine.disease ,MESH: Male ,chemistry ,Immunology ,MESH: Viral Nonstructural Proteins ,business ,MESH: Female ,[ SDV.BBM.BS ] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biomolecules [q-bio.BM] - Abstract
The pretherapeutic presence of protease inhibitor (PI) resistance-associated variants (RAVs) has not been shown to be predictive of triple-therapy outcomes in treatment-naive patients. However, they may influence the outcome in patients with less effective pegylated interferon (pegIFN)-ribavirin (RBV) backbones. Using hepatitis C virus (HCV) population sequence analysis, we retrospectively investigated the prevalence of baseline nonstructural 3 (NS3) RAVs in a multicenter cohort of poor IFN-RBV responders (i.e., prior null responders or patients with a viral load decrease of 3-fold shift in 50% inhibitory concentration (IC 50 ) for telaprevir or boceprevir, T54S was the most frequently detected mutation (3.9%), followed by A156T, R155K (0.7%), V36M, and V55A (0.35%). Mutations were more frequently found in patients infected with genotype 1a (7.5 to 23.6%) than 1b (3.3 to 19.8%) ( P = 0.03). No other sociodemographic or viroclinical characteristic was significantly associated with a higher prevalence of RAVs. No obvious effect of baseline RAVs on viral load was observed. In this cohort of poor responders to IFN-RBV, no link was found with a sustained virological response to triple therapy, regardless of the algorithm used for the detection of mutations. Based on a cross-study comparison, baseline RAVs are not more frequent in poor IFN-RBV responders than in treatment-naive patients and, even in these difficult-to-treat patients, this study demonstrates no impact on treatment outcome, arguing against resistance analysis prior to treatment.
- Published
- 2015
33. New HIV-1 circulating recombinant form 94: from phylogenetic detection of a large transmission cluster to prevention in the age of geosocial-networking apps in France, 2013 to 2017.
- Author
-
Wirden, Marc, De Oliveira, Fabienne, Bouvier-Alias, Magali, Lambert-Niclot, Sidonie, Chaix, Marie-Laure, Raymond, Stéphanie, Si-Mohammed, Ali, Alloui, Chakib, André-Garnier, Elisabeth, Bellecave, Pantxika, Malve, Brice, Mirand, Audrey, Pallier, Coralie, Poveda, Jean-Dominique, Rabenja, Theresa, Schneider, Veronique, Signori-Schmuck, Anne, Stefc, Karl, Calvez, Vincent, and Descamps, Diane
- Published
- 2019
- Full Text
- View/download PDF
34. Stable prevalence of transmitted drug resistance mutations and increased circulation of non-B subtypes in antiretroviral-naive chronically HIV-infected patients in 2015/2016 in France.
- Author
-
Assoumou, Lambert, Bocket, Laurence, Pallier, Coralie, Grude, Maxime, Ait-Namane, Rachid, Izopet, Jacques, Raymond, Stéphanie, Charpentier, Charlotte, Visseaux, Benoit, Wirden, Marc, Trabaud, Mary-Anne, Guillou-Guillemette, Hélène Le, Allaoui, Chakib, Henquell, Cécile, Krivine, Anne, Santos, Georges Dos, Delamare, Catherine, Bouvier-Alias, Magali, Montes, Brigitte, and Ferre, Virginie
- Subjects
DRUG resistance ,ANTIRETROVIRAL agents ,HIV infections ,INTEGRASE inhibitors ,SAFE sex - Abstract
Objectives: We estimated the prevalence of transmitted-drug-resistance-associated mutations (TDRAMs) in antiretroviral-naive chronically HIV-1-infected patients.Patients and Methods: TDRAMs were sought in samples from 660 diagnosed HIV-1-infected individuals in 2015/2016 in 33 HIV clinical centres. Weighted analyses, considering the number of patients followed in each centre, were used to derive representative estimates of the percentage of individuals with TDRAMs. Results were compared with those of the 2010/2011 survey (n = 661) using the same methodology.Results: At inclusion, median CD4 cell counts and plasma HIV-1 RNA were 394 and 350/mm3 (P = 0.056) and 4.6 and 4.6 log10 copies/mL (P = 0.360) in the 2010/2011 survey and the 2015/2016 survey, respectively. The frequency of non-B subtypes increased from 42.9% in 2010/2011 to 54.8% in 2015/2016 (P < 0.001), including 23.4% and 30.6% of CRF02_AG (P = 0.004). The prevalence of virus with protease or reverse-transcriptase TDRAMs was 9.0% (95% CI = 6.8-11.2) in 2010/2011 and 10.8% (95% CI = 8.4-13.2) in 2015/2016 (P = 0.269). No significant increase was observed in integrase inhibitor TDRAMs (6.7% versus 9.2%, P = 0.146). Multivariable analysis showed that men infected with the B subtype were the group with the highest risk of being infected with a resistant virus compared with others (adjusted OR = 2.2, 95% CI = 1.3-3.9).Conclusions: In France in 2015/2016, the overall prevalence of TDRAMs was 10.8% and stable compared with 9.0% in the 2010/2011 survey. Non-B subtypes dramatically increased after 2010. Men infected with B subtype were the group with the highest risk of being infected with a resistant virus, highlighting the need to re-emphasize safe sex messages. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
35. Liver stiffness diminishes with antiviral response in chronic hepatitis C
- Author
-
Hézode, Christophe, Castéra, Laurent, Roudot-Thoraval, Françoise, Bouvier-Alias, Magali, Rosa, Isabelle, Roulot, Dominique, Leroy, Vincent, Mallat, Ariane, Pawlotsky, Jean-Michel, Service d'hépato-gastro-entérologie [APHP Henri Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service d'hépatologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de santé publique [Mondor], Centre National de Référence Virus des hépatites B, C et Delta, Institut National de la Transfusion Sanguine [Paris] (INTS)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'hépato-gastro-entérologie, CHI Créteil, Service de Gastro-entérologie [Avicenne], Université Paris 13 (UP13)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Avicenne [AP-HP], Département d'hépato-gastroentérologie, and CHU Grenoble-Université Grenoble Alpes (UGA)
- Subjects
Adult ,Liver Cirrhosis ,Male ,Interferon-alpha ,Hepatitis C, Chronic ,Interferon alpha-2 ,Middle Aged ,Antiviral Agents ,Recombinant Proteins ,Polyethylene Glycols ,Liver ,Multivariate Analysis ,Ribavirin ,Elasticity Imaging Techniques ,Humans ,Female ,[SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology ,France ,Prospective Studies - Abstract
International audience; Aliment Pharmacol Ther 2011; 34: 656-663 SUMMARY: Background Transient elastography measures liver stiffness, which correlates with the hepatic fibrosis stage and has excellent accuracy for the diagnosis of cirrhosis in patients with chronic hepatitis C. Aim To assess prospectively the kinetics of liver stiffness in treated patients with chronic hepatitis C and compare them with the viral kinetics on treatment and with the final outcome of therapy. Methods 91 patients with chronic hepatitis C with significant fibrosis (>7.0 kPa) at baseline were included. They received therapy with pegylated interferon-α and ribavirin. The kinetics of liver stiffness were characterized during therapy and thereafter by means of Fibroscan, and compared with the virological responses at weeks 4, 12, 24, end of treatment and 12 and 24 weeks after. Results A significant liver stiffness decrease was observed during therapy, which continued after treatment only in patients who achieved a sustained virological response. In this group, the median intra-patient decrease relative to baseline at the end of follow-up was -3.4 kPa, vs-1.8 kPa in the patients who did not achieve an SVR. Similar dynamics were observed in cirrhotic and non-cirrhotic patients. In multivariate analysis, only the SVR was associated with long-term improvement of liver stiffness (odds ratio: 3.10; 95% confidence interval: 1.20-8.02, P = 0.019). Conclusions In patients with advanced fibrosis at the start of therapy, liver stiffness is significantly reduced during treatment, but improvement continues off treatment only in patients who achieve a sustained virological response. Liver stiffness assessment earlier than 6 months after the end of therapy does not appear to be clinically meaningful.
- Published
- 2011
36. High-Dose Pegylated Interferon-α and Ribavirin in Nonresponder Hepatitis C Patients and Relationship With IL-28B Genotype (SYREN Trial)
- Author
-
Chevaliez, Stéphane, Hézode, Christophe, Soulier, Alexandre, Costes, Bruno, Bouvier-Alias, Magali, Rouanet, Stéphanie, Foucher, Juliette, Bronowicki, Jean-Pierre, Tran, Albert, Rosa, Isabelle, Mathurin, Philippe, Alric, Laurent, Leroy, Vincent, Couzigou, Patrice, Mallat, Ariane, Charaf-Eddine, Mariem, Babany, Gérard, Pawlotsky, Jean-Michel, Centre National de Référence Virus des hépatites B, C et Delta, Institut National de la Transfusion Sanguine [Paris] (INTS)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10, Service d'hépato-gastro-entérologie [APHP Henri Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service de Biochimie [Mondor], Produits Roche, Roche, Département d'hépatologie et de gastroentérologie, Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Pôle Digestif, Hôpital Archet 2 [Nice] (CHU), Service d'hépato-gastro-entérologie, CHI Créteil, Service d'Hépato-gastroentérologie, Hôpital Huriez-Université de Lille, Service de médecine interne et maladies digestives, CHU Toulouse [Toulouse], Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, This study is investigator-initiated. It has been funded by Roche France, which provided the study drugs, Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service Médecine Interne et immunologie clinique [CHU Toulouse], Pôle Maladies de l'appareil digestif [CHU Toulouse], and Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)
- Subjects
Hepatitis C virus ,nonresponder ,[SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology ,IL28B genotype ,high-dose pegylated IFN-α - Abstract
International audience; BACKGROUND & AIMS: In patients with chronic hepatitis C who failed to respond to standard therapy, high-dose pegylated interferon (IFN)-α and/or ribavirin could induce a stronger antiviral response and prevent treatment failure and HCV resistance when combined with direct-acting antivirals. The influence of genetic determinants in this context remains unknown. METHODS: Eighty-three patients infected with HCV genotype 1 who were nonresponsive to standard therapy received pegylated IFN-α2a (360 μg once per week or 180 μg twice per week) with ribavirin (1.0-1.2 or 1.2-1.6 g/d) for up to 72 weeks. Virological responses were assessed at different time points, and the influence of the IL-28B genotype was studied. RESULTS: At weeks 12 and 24, respectively, 47 (56.6%) and 50 (60.2%) patients achieved a ≥2-Log(10) decrease of HCV RNA levels; 8 (9.6%) and 21 (25.3%) patients had undetectable HCV RNA after 12 and 24 weeks of treatment, respectively. Patients with a CT IL-28B genotype responded significantly better and earlier than those with a TT genotype. In multivariate analysis, the IL-28B genotype was an independent predictor of the virological responses at weeks 4, 12, and 24. CONCLUSIONS: High-dose pegylated IFN-α with standard or high doses of ribavirin induces a potent antiviral response in a substantial number of patients who did not respond to standard therapy. The IL-28B genotype is an independent predictor of the antiviral response. High-dose pegylated IFN-α in combination with ribavirin and protease inhibitors appears as an attractive option for future study in this population.
- Published
- 2011
37. CAP/CTM VERSION 2.0 FOR HBV DNA QUANTIFICATION
- Author
-
Chevaliez, Stéphane, Bouvier-Alias, Magali, Laperche, Syria, Hézode, Christophe, Pawlotsky, Jean-Michel, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10, Centre National de Référence Virus des hépatites B, C et Delta, Institut National de la Transfusion Sanguine [Paris] (INTS)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'hépato-gastro-entérologie [APHP Henri Mondor], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)
- Subjects
MESH: Humans ,MESH: Hepatitis B ,MESH: Time Factors ,virus diseases ,MESH: Polymerase Chain Reaction ,MESH: Serum ,MESH: Sensitivity and Specificity ,MESH: DNA, Viral ,MESH: Reproducibility of Results ,MESH: Hepatitis B virus ,MESH: Automation ,[SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology ,MESH: Viral Load ,MESH: Plasma - Abstract
International audience; The detection and quantification of hepatitis B virus (HBV) DNA are essential for the diagnosis and treatment of chronic HBV infection. The use of real-time PCR assays for HBV DNA quantification is strongly recommended. The goal of this study was to evaluate the intrinsic characteristics and clinical performance of version 2.0 (v2.0) of the Cobas AmpliPrep/Cobas TaqMan (CAP/CTM) assay, a fully automated platform for HBV DNA quantification in serum or in plasma with a claimed lower limit of detection of 20 IU/ml and a claimed upper limit of quantification of 1.7 × 10(8) IU/ml. The specificity of the assay was 99% (95% confidence interval, 94.7 to 100%). Intra-assay and interassay coefficients of variation ranged from 0.21% to 2.67% and from 0.65% to 2.25%, respectively. The calibration of the assay was found to be satisfactory. Study of blood specimens from patients infected with HBV genotypes A to F showed good correspondence between HBV DNA levels measured by the CAP/CTM v2.0 assay, version 1.0 of the same assay, and the third-generation "branched DNA" assay. The CAP/CTM v2.0 assay quantified HBV DNA levels in serum or plasma from the same patients equally. In conclusion, the new version of the CAP/CTM assay is sensitive, specific, and reproducible. It accurately quantifies HBV DNA levels in patients chronically infected with HBV genotypes A to F. Improvements made to ensure equal quantification of HBV DNA in serum and plasma have been successful. Overall, the CAP/CTM assay, version 2.0, is well suited to monitoring clinical HBV DNA levels according to current clinical practice guidelines.
- Published
- 2010
38. Performance of the Abbott real-time PCR assay using m2000sp and m2000rt for hepatitis C virus RNA quantification
- Author
-
Chevaliez, Stéphane, Bouvier-Alias, Magali, Pawlotsky, Jean-Michel, Centre National de Référence Virus des hépatites B, C et Delta, Institut National de la Transfusion Sanguine [Paris] (INTS)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Mondor de recherche biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), and This work is part of the activity of the VIRGIL European Network of Excellence on Antiviral Drug Resistance supported by a grant (LSHM-CT-2004-503359) from the Priority 1 'Life Sciences, Genomics and Biotechnology for Health' programme in the 6th Framework Programme of the European Union
- Subjects
[SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology - Abstract
International audience; Quantification of hepatitis C virus (HCV) RNA is essential for the everyday management of chronic hepatitis C therapy. "Real-time" PCR techniques are potentially more sensitive than classical PCR techniques, are not prone to carryover contamination, and have a consistently wider dynamic range of quantification. Thus, they are rapidly replacing other technologies for routine quantification of HCV RNA. We extensively evaluated the intrinsic characteristics and clinical performance of the m2000(sp)-m2000(rt) Abbott real-time PCR platform for HCV RNA quantification. The study shows that the m2000(sp)-m2000(rt) platform is sensitive, specific, and precise; that the results are reproducible; and that the platform has a broad dynamic range of quantification. When comparing HCV RNA levels measured in the same individuals with the m2000(sp)-m2000(rt) platform and the third-generation branched-DNA assay, a trend toward a modest overestimation of HCV RNA levels was observed in the m2000(sp)-m2000(rt) platform in all genotypes except genotype 5. The differences, however, were unlikely to have any impact in clinical practice. In conclusion, our study shows that the Abbott m2000 real-time PCR system for HCV RNA quantification is sensitive, specific, and precise; that the results are reproducible; and that the platform's broad dynamic range of quantification is well suited to HCV RNA monitoring in the clinical setting.
- Published
- 2009
39. Clinical utility of hepatitis C virus core antigen quantification in patients with chronic hepatitis C
- Author
-
Chevaliez, Stéphane, primary, Soulier, Alexandre, additional, Poiteau, Lila, additional, Bouvier-Alias, Magali, additional, and Pawlotsky, Jean-Michel, additional
- Published
- 2014
- Full Text
- View/download PDF
40. The Cobas AmpliPrep/Cobas TaqMan HCV Test, Version 2.0, Real-Time PCR Assay Accurately Quantifies Hepatitis C Virus Genotype 4 RNA
- Author
-
Chevaliez, Stéphane, primary, Bouvier-Alias, Magali, additional, Rodriguez, Christophe, additional, Soulier, Alexandre, additional, Poveda, Jean-Dominique, additional, and Pawlotsky, Jean-Michel, additional
- Published
- 2013
- Full Text
- View/download PDF
41. Pegylated Interferon α-2a Triggers NK-Cell Functionality and Specific T-Cell Responses in Patients with Chronic HBV Infection without HBsAg Seroconversion.
- Author
-
Bruder Costa, Juliana, Dufeu-Duchesne, Tania, Leroy, Vincent, Bertucci, Inga, Bouvier-Alias, Magali, Pouget, Noelle, Brevot-Lutton, Ophelie, Bourliere, Marc, Zoulim, Fabien, Plumas, Joel, Aspord, Caroline, and null, null
- Subjects
CHRONIC hepatitis B ,INTERFERONS ,KILLER cells ,T cells ,HEPATITIS associated antigen ,SEROCONVERSION - Abstract
Pegylated interferon α-2a (Peg-IFN-α) represents a therapeutic alternative to the prolonged use of nucleos(t)ide analog (NA) in chronic hepatitis B (CHB) infection. The mechanisms leading to a positive clinical outcome remain unclear. As immune responses are critical for virus control, we investigated the effects of Peg-IFN-α on both innate and adaptive immunity, and related it to the clinical evolution. The phenotypic and functional features of the dendritic cells (DCs), natural killer (NK) cells and HBV-specific CD4/CD8 T cells were analyzed in HBeAg-negative CHB patients treated for 48-weeks with NA alone or together with Peg-IFN-α, before, during and up to 2-years after therapy. Peg-IFN-α induced an early activation of DCs, a potent expansion of the CD56
bright NK subset, and enhanced the activation and functionality of the CD56dim NK subset. Peg-IFN-α triggered an increase in the frequencies of Th1- and Th17-oriented HBV-specific CD4/CD8 T cells. Peg-IFN-α reversed the unresponsiveness of patients to a specific stimulation. Most of the parameters returned to baseline after the stop of Peg-IFN-α therapy. Peg-IFN-α impacts both innate and adaptive immunity, overcoming dysfunctional immune responses in CHB patients. These modulations were not associated with seroconversion, which questioned the benefit of the add-on Peg-IFN-α treatment. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
42. Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination
- Author
-
Sokal, Aurélien, Bastard, Paul, Chappert, Pascal, Barba-Spaeth, Giovanna, Fourati, Slim, Vanderberghe, Alexis, Lagouge-Roussey, Pauline, Meyts, Isabelle, Gervais, Adrian, Bouvier-Alias, Magali, Azzaoui, Imane, Fernández, Ignacio, de la Selle, Andréa, Zhang, Qian, Bizien, Lucy, Pellier, Isabelle, Linglart, Agnès, Rothenbuhler, Anya, Marcoux, Estelle, Anxionnat, Raphael, Cheikh, Nathalie, Léger, Juliane, Amador-Borrero, Blanca, Fouyssac, Fanny, Menut, Vanessa, Goffard, Jean-Christophe, Storey, Caroline, Demily, Caroline, Mallebranche, Coralie, Troya, Jesus, Pujol, Aurora, Zins, Marie, Tiberghien, Pierre, Gray, Paul E., McNaughton, Peter, Sullivan, Anna, Peake, Jane, Levy, Romain, Languille, Laetitia, Rodiguez-Gallego, Carlos, Boisson, Bertrand, Gallien, Sébastien, Neven, Bénédicte, Michel, Marc, Godeau, Bertrand, Abel, Laurent, Rey, Felix A., Weill, Jean-Claude, Reynaud, Claude-Agnès, Tangye, Stuart G., Casanova, Jean-Laurent, and Mahévas, Matthieu
- Abstract
Inborn and acquired deficits of type I interferon (IFN) immunity predispose to life-threatening COVID-19 pneumonia. We longitudinally profiled the B cell response to mRNA vaccination in SARS-CoV-2 naive patients with inherited TLR7, IRF7, or IFNAR1 deficiency, as well as young patients with autoantibodies neutralizing type I IFNs due to autoimmune polyendocrine syndrome type-1 (APS-1) and older individuals with age-associated autoantibodies to type I IFNs. The receptor-binding domain spike protein (RBD)–specific memory B cell response in all patients was quantitatively and qualitatively similar to healthy donors. Sustained germinal center responses led to accumulation of somatic hypermutations in immunoglobulin heavy chain genes. The amplitude and duration of, and viral neutralization by, RBD-specific IgG serological response were also largely unaffected by TLR7, IRF7, or IFNAR1 deficiencies up to 7 mo after vaccination in all patients. These results suggest that induction of type I IFN is not required for efficient generation of a humoral response against SARS-CoV-2 by mRNA vaccines.
- Published
- 2023
- Full Text
- View/download PDF
43. Interpretation of Real-Time PCR Results for Hepatitis C Virus RNA When Viral Load Is Below Quantification Limits
- Author
-
Laperche, Syria, primary, Bouchardeau, Françoise, additional, André-Garnier, Elisabeth, additional, Thibault, Vincent, additional, Roque-Afonso, Anne-Marie, additional, Trimoulet, Pascale, additional, Colimon, Ronald, additional, Duverlie, Gilles, additional, Leguillou-Guillemette, Hélène, additional, Lunel, Françoise, additional, Bouvier-Alias, Magali, additional, Pawlotsky, Jean-Michel, additional, Henquell, Cécile, additional, Schvoerer, Evelyne, additional, Stoll-Keller, Françoise, additional, Chaix, Marie-Laure, additional, Branger, Michel, additional, Gaudy-Graffin, Catherine, additional, Rosenberg, Arielle R., additional, Pozzetto, Bruno, additional, Vallet, Sophie, additional, Baazia, Yazid, additional, Izopet, Jacques, additional, and Lefrère, Jean-Jacques, additional
- Published
- 2011
- Full Text
- View/download PDF
44. Performance of Version 2.0 of the Cobas AmpliPrep/Cobas TaqMan Real-Time PCR Assay for Hepatitis B Virus DNA Quantification
- Author
-
Chevaliez, Stéphane, primary, Bouvier-Alias, Magali, additional, Laperche, Syria, additional, Hézode, Christophe, additional, and Pawlotsky, Jean-Michel, additional
- Published
- 2010
- Full Text
- View/download PDF
45. Factors Associated with Virological Response to Etravirine in Nonnucleoside Reverse Transcriptase Inhibitor-Experienced HIV-1-Infected Patients
- Author
-
Marcelin, Anne-Genevieve, primary, Flandre, Philippe, additional, Descamps, Diane, additional, Morand-Joubert, Laurence, additional, Charpentier, Charlotte, additional, Izopet, Jacques, additional, Trabaud, Mary-Anne, additional, Saoudin, Henia, additional, Delaugerre, Constance, additional, Tamalet, Catherine, additional, Cottalorda, Jacqueline, additional, Bouvier-Alias, Magali, additional, Bettinger, Dominique, additional, Dos Santos, Georges, additional, Ruffault, Annick, additional, Alloui, Chakib, additional, Henquell, Cecile, additional, Rogez, Sylvie, additional, Barin, Francis, additional, Signori-Schmuck, Anne, additional, Vallet, Sophie, additional, Masquelier, Bernard, additional, and Calvez, Vincent, additional
- Published
- 2010
- Full Text
- View/download PDF
46. Hepatitis C Virus (HCV) Genotype 1 Subtype Identification in New HCV Drug Development and Future Clinical Practice
- Author
-
Chevaliez, Stéphane, primary, Bouvier-Alias, Magali, additional, Brillet, Rozenn, additional, and Pawlotsky, Jean-Michel, additional
- Published
- 2009
- Full Text
- View/download PDF
47. Performance of the Abbott Real-Time PCR Assay Using m 2000 sp and m 2000 rt for Hepatitis C Virus RNA Quantification
- Author
-
Chevaliez, Stéphane, primary, Bouvier-Alias, Magali, additional, and Pawlotsky, Jean-Michel, additional
- Published
- 2009
- Full Text
- View/download PDF
48. The Cobas AmpliPrep-Cobas TaqMan real-time polymerase chain reaction assay fails to detect hepatitis C virus RNA in highly viremic genotype 4 clinical samples
- Author
-
Chevaliez, Stéphane, primary, Bouvier-Alias, Magali, additional, Castéra, Laurent, additional, and Pawlotsky, Jean-Michel, additional
- Published
- 2008
- Full Text
- View/download PDF
49. Tipranavir-Ritonavir Genotypic Resistance Score in Protease Inhibitor-Experienced Patients
- Author
-
Marcelin, Anne-Genevieve, primary, Masquelier, Bernard, additional, Descamps, Diane, additional, Izopet, Jacques, additional, Charpentier, Charlotte, additional, Alloui, Chakib, additional, Bouvier-Alias, Magali, additional, Signori-Schmuck, Anne, additional, Montes, Brigitte, additional, Chaix, Marie-Laure, additional, Amiel, Corinne, additional, Santos, Georges Dos, additional, Ruffault, Annick, additional, Barin, Francis, additional, Peytavin, Gilles, additional, Lavignon, Marc, additional, Flandre, Philippe, additional, and Calvez, Vincent, additional
- Published
- 2008
- Full Text
- View/download PDF
50. Performance of the Cobas AmpliPrep/Cobas TaqMan Real-Time PCR Assay for Hepatitis B Virus DNA Quantification
- Author
-
Chevaliez, Stéphane, primary, Bouvier-Alias, Magali, additional, Laperche, Syria, additional, and Pawlotsky, Jean-Michel, additional
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.